Ont Health Technol Assess Ser. 2013 Nov 1;13(23):1-45. eCollection 2013.
More than 2.9 million serum vitamin B12 tests were performed in 2010 in Ontario at a cost of $40 million. Vitamin B12 deficiency has been associated with a few neurocognitive disorders.
To determine the clinical utility of B12 testing in patients with suspected dementia or cognitive decline.
Three questions were addressed: Is there an association between vitamin B12 deficiency and the onset of dementia or cognitive decline? Does treatment with vitamin B12 supplementation improve cognitive function in patients with dementia or cognitive decline and vitamin B12 deficiency? What is the effectiveness of oral versus parenteral vitamin B12 supplementation in those with confirmed vitamin B12 deficiency? A literature search was performed using MEDLINE, Embase, EBSCO Cumulative Index to Nursing & Allied Health Literature (CINAHL), the Cochrane Library, and the Centre for Reviews and Dissemination database, from January 2002 until August 2012.
Eighteen studies (7 systematic reviews and 11 observational studies) were identified to address the question of the association between B12 and the onset of dementia. Four systematic reviews were identified to address the question of the treatment of B12 on cognitive function. Finally, 3 randomized controlled trials were identified that compared oral B12 to intramuscular B12.
Based on very low quality evidence, there does appear to be an association between elevated plasma homocysteine levels (a by-product of B vitamins) and the onset of dementia. Based on moderate quality evidence, but with less than optimal duration of follow-up, treatment with B12 supplementation does not appreciably change cognitive function. Based on low to moderate quality of evidence, treatment with vitamin B12 and folate in patients with mild cognitive impairment seems to slow the rate of brain atrophy. Based on moderate quality evidence, oral vitamin B12 is as effective as parenteral vitamin B12 in patients with confirmed B12 deficiency.
Low levels of vitamin B12 have been associated with neurocognitive disorders. This evidence-based analysis assessed the usefulness of serum vitamin B12 testing as it relates to brain function. This review found very low quality evidence that suggests a connection between high plasma homocysteine levels (a by-product of B vitamin metabolism in the body) and the onset of dementia. Moderate quality of evidence indicates treatment with vitamin B12 does not improve brain function. Moderate quality of evidence also indicates treatment using oral vitamin B12 supplements is as effective as injections of vitamin B12.
2010年安大略省进行了超过290万次血清维生素B12检测,花费4000万美元。维生素B12缺乏与一些神经认知障碍有关。
确定对疑似痴呆或认知功能减退患者进行B12检测的临床实用性。
探讨了三个问题:维生素B12缺乏与痴呆或认知功能减退的发病之间是否存在关联?补充维生素B12治疗能否改善痴呆或认知功能减退且维生素B12缺乏患者的认知功能?对于确诊维生素B12缺乏的患者,口服与胃肠外补充维生素B12的效果如何?使用MEDLINE、Embase、EBSCO护理及相关健康文献累积索引(CINAHL)、Cochrane图书馆以及综述与传播中心数据库,检索了2002年1月至2012年8月的文献。
共确定了18项研究(7项系统评价和11项观察性研究)来探讨B12与痴呆发病之间的关联问题。确定了4项系统评价来探讨B12对认知功能的治疗问题。最后,确定了3项比较口服B12与肌肉注射B12的随机对照试验。
基于质量极低的证据,血浆同型半胱氨酸水平(B族维生素的一种副产品)升高与痴呆发病之间似乎确实存在关联。基于质量中等的证据,但随访时间未达最佳时长,补充B12治疗并不能明显改变认知功能。基于质量低至中等的证据,对轻度认知障碍患者使用维生素B12和叶酸治疗似乎能减缓脑萎缩速度。基于质量中等的证据,对于确诊B12缺乏的患者,口服维生素B12与胃肠外补充维生素B12效果相同。
维生素B12水平低与神经认知障碍有关。这项基于证据的分析评估了血清维生素B12检测与脑功能相关的实用性。该综述发现质量极低的证据表明血浆高同型半胱氨酸水平(体内B族维生素代谢的一种副产品)与痴呆发病之间存在联系。质量中等的证据表明维生素B12治疗不能改善脑功能。质量中等的证据还表明口服维生素B12补充剂与注射维生素B12效果相同。